3-(2-phenylethenyl)pyridazine | 1135-31-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-phenylethenyl)pyridazine
• 英文别名: 3-(2-phenylvinyl)pyridazine；3-styrylpyridazine
• CAS: 1135-31-5
• 化学式: C₁₂H₁₀N₂
• 分子量: 182.225
• InChiKey: CNYDPKJPMBRDPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-phenylethenyl)pyridazine 在 sodium periodate 、 四氧化锇 作用下， 以 水 、 丙酮 、 叔丁醇 为溶剂， 反应 48.0h， 以81%的产率得到哒嗪-3-甲醛
  参考文献：
  名称：

  Synthesis and structure–activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists

  摘要：

  A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V-2 receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V-2 binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V-1a receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V-2 receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.03.001
• 作为产物：
  描述：

  3-甲基哒嗪 、 苯甲醛 在 氯化锌 sodium hydroxide 、 silica gel 、 乙酸乙酯 、 二氯甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 以furnished 2.820 g (77%) of 3-styrylpyridazine as a pale brown solid的产率得到3-(2-phenylethenyl)pyridazine
  参考文献：
  名称：

  VIRAL REPLICATION INHIBITORS

  摘要：

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。

  公开号：

  US20140213586A1

文献信息

• Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
  申请人：——

  公开号：US20010039271A1

  公开（公告）日：2001-11-08

  Compounds of the formulae (IA) and (IB): 1 wherein R 1 is C 1 to C 3 alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C 1 to C 4 alkoxy; halo; CN; CF 3 ; OCF 3 or C 1 to C 4 alkyl wherein said C 1 to C 4 alkyl group is optionally substituted by C 1 to C 4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R 2 is C 1 to C 6 alkyl and R 13 is OR 3 or NR 5 R 6 , or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

  式(I-A)和(I-B)的化合物：其中，R1是C1到C3烷基，可选地被苯基，Het或选择自哌啶基和吗啉基的N-连接杂环基团取代；其中，所述苯基可选地被一个或多个取代基所取代，所述取代基选择自C1到C4烷氧基，卤素，CN，CF3，OCF3或C1到C4烷基，其中所述C1到C4烷基可选地被C1到C4卤代烷基或卤代烷氧基所取代，所述卤代烷基或卤代烷氧基中的任意一个被一个或多个卤素原子所取代；R2是C1到C6烷基，R13是OR3或NR5R6，或其药学上或兽医学上可接受的盐，或者是上述任一实体的药学上或兽医学上可接受的溶剂，它们是选择性抑制剂5型环鸟苷酸3′，5′-单磷酸磷酸二酯酶（cGMP PDE5）的有效药物，并且在治疗男性勃起功能障碍（MED）和女性性功能障碍（FSD）等方面具有用途。
• Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Pt: MVol.D, 268, page 586 - 588
  作者：

  DOI：——

  日期：——
• Poppenberg, O., Chemische Berichte, 1901, vol. 34, p. 3257 - 3267
  作者：Poppenberg, O.

  DOI：——

  日期：——
• Synthesis and structure–activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists
  作者：Issei Tsukamoto、Hiroyuki Koshio、Takahiro Kuramochi、Chikashi Saitoh、Hiroko Yanai-Inamura、Chika Kitada-Nozawa、Eisaku Yamamoto、Takeyuki Yatsu、Yoshiaki Shimada、Shuichi Sakamoto、Shin-ichi Tsukamoto

  DOI：10.1016/j.bmc.2009.03.001

  日期：2009.4

  A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V-2 receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V-2 binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V-1a receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V-2 receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats. (C) 2009 Elsevier Ltd. All rights reserved.
• VIRAL REPLICATION INHIBITORS
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

  公开号：US20140213586A1

  公开（公告）日：2014-07-31

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。